Background: Adequate molecular risk stratification is crucial for modern management of chronic lymphocytic leukemia (CLL) patients. Expression of zeta associated protein -70 (ZAP-70) has been proposed as a surrogate marker for the immunoglobulin variable region (VH) mutation status, and is associated with poor prognosis in CLL. Although recent studies have shown that presence of high-risk cytogenetic/ molecular factors (del11q, del17p, V3-21 usage) can result in discordance between ZAP-70 expression and VH mutation status, a direct comparison of ZAP-70 expression as measured by multiparametric flow cytometry, with low to intermediate cytogenetic risk factors (del13q and trisomy 12), has not been characterized. Understanding this relationship has practical significance since the VH mutation status can not be evaluated as a routine clinical test. Design: Data was retrospectively collected from 81 CLL patients who had both ZAP-70 and cytogenetic studies performed between 01/2005 and 09/2007. Patients with the following characteristics were excluded: presence of high risk cytogenetics as mentioned above; lack of either trisomy 12 or del 13q; simultaneous expression of trisomy 12 and del 13q; plus more than 2 concurrent cytogenetic abnormalities. The remaining patients (n = 38) were then separated into two groups, based on the presence of either trisomy 12 or del13q, identified by FISH. The average percent of ZAP-70 expression by multiparametric flow cytometry was compared using the student T test. Molecular genetic studies for the VH mutation status were not performed in this study. Results: There was a statistically significant lower level of ZAP-70 expression in the del13q group (mean ZAP 70 % expression=9.16%) when compared with the trisomy 12 group (mean ZAP 70% expression=19.90%) (p=0.005).
evaluated utility of a molecular fixative (UMFIX, Sakura Finetek USA, Inc, Torrance, CA) for its effect on quality of tissue morphology and on preservation of DNA and RNA integrity. Design: Forty surgical specimens: colon (11), breast (13), lung (6), prostate (8), kidney (1), and skin (2) were split in 3 equal parts, and tissues were immediately fixed in a) UMFIX, b) NBF, and c) snap frozen. The tissues were all quality controlled morphologically. DNA and RNA were isolated from approximately equal number of tissue sections. Quality and quantity was evaluated by spectrophotometry and agarose gel electrophoresis. Integrity of isolated DNA was assessed by amplification of 100, 200, 300, 400, and 600 base pair (bp) amplicons. For assessment of RNA integrity, amplification of β-Actin (4 and 705 bp fragments) and β2 microglobulin (less than 200 bp fragment) transcripts was utilized. Results: The histomorphology of UMFIX-fixed tissues was similar to that of matched FFPE tissues. UMFIX fixation preserved integrity of small and intermediate DNA fragments, as demonstrated by successful amplification of 400 bp amplicons in all samples, and 600 bp amplicons in 17/40 (43%) samples. RNA integrity of UMFIXfixed tissue was 45% and 43% of that observed for frozen tissue in amplification of 243 and 705 bp β-Actin fragments, respectively. UMFIX fixation proved inferior to both freezing and formalin fixation in amplification of β2 microglobulin transcripts (104 versus 215,168 and 1,047 copies, respectively). Length of fixation time did not seem to influence the quality of nucleic acids. Conclusions: Histomorphology of UMFIX-fixed tissues was similar to that of FFPE tissues, and was diagnostic. UMFIX also proved superior to formalin in preservation of DNA integrity, yet was only 40% as effective as snap freezing in preserving larger DNA fragments. UMFIX performed poorly in preservation of RNA. Overall, while UMFIX proved acceptable for tissue morphology, it failed to preserve total nucleic acid integrity to a degree that would justify its use as a universal molecular fixative.
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Lean Process Improvement Shortens Total Molecular Diagnostic Testing Time M Cankovic, L Whiteley, R Brown, R D'Angelo, RJ Zarbo. Henry Ford Hospital, Detroit, MI. Background: Diagnostic molecular test results are often important for subsequent therapeutic decision making, yet delays during the pre-analytic phase of test ordering and specimen retrieval greatly influence the overall turnaround times (TAT). These delays are often caused by lack of co-ordination in specimen hand-offs between different sections of the lab. In this study we share our experience with the Henry Ford Production System's implementation of Lean process improvements across different disciplines that resulted in significantly reduced TAT for antigen rearrangement (AR) assays. Design: We compared total test times and individual steps in 3 time periods, and measured the time it took to complete different steps. Period I -By looking at a two year period, we estimated average times needed to complete the following steps: 1. Pathologist realizes the AR testing is needed; 2. Pathologist orders the test; 3. Molecular Diagnostic lab requests Histology to cut appropriate tissue sections; 4. Histology assigns low priority to task; 5. Molecular Diagnostic lab completes the testing. Period II -Lean Process improvements were implemented across different disciplines; we measured the time it took to complete the 5 steps defined in Phase I. Period III -Several "Rapid Process Improvement" modifications were added to further increase efficiency. Results: Period I -The entire process, from the time the pathologist realizes the testing is needed to the time the test results are generated took from .5-145 hours (1.4-6.0 days); average 64.8 hours (2.7 days). A lot of this time was wasted on hand-offs between different lab sections. In Period II, electronic test ordering became available, and Lean process improvement was implemented in Histology for continuous work process. This resulted in elimination of 2 pre-analytical steps, and significant reduction in time for 2 additional steps. In Period III, visual aids were made available to Histology personnel in order to reduce misunderstanding of electronic requests and reduce need for re-cuts. This resulted in additional time saving, and TATs of 24.2-49 hours (1-2 days); average 6.5 hours (1.5 days). Conclusions: By implementing Lean processes across laboratory disciplines, total molecular diagnostic time for AR assays was reduced from an average of 2.7 days to an average of 1.5 days, a 45% improvement. Because of the more timely molecular diagnostic test results, pathologists were able to rapidly integrate this information in a final report without need for an addendum report. Background: Studies evaluating the routine papanicolaou (pap) test have traditionally used as the reference gold standard, the diagnoses on the follow-up cervical histologic samples. Since the latter are typically obtained days to weeks after the cytologic sample, the accuracy of the resultant comparison may be affected by intervening factors, such as regression of human papillomavirus or colposcopy-associated variability. A subset of our clinicians have routinely obtained cervical cytology samples immediately prior to their colposcopic procedures, which presented a unique opportunity to re-evaluate the test performance of the pap test in detecting the most clinically significant lesions (i.e cervical intraepithelial neoplasia 2 or worse: CIN2+), using as gold standard, diagnoses on cervical biopsies that were essentially obtained simultaneously. Design: Our database was searched for all women with a cervical biopsy (bx) and pap test accessioned within 24 hours of each other for the period 1/3/06-7/27/07. For each patient, diagnostic discordance between the pap test and bx was considered to be present when either modality displayed HSIL/CIN2+ while the other modality displayed no dysplasia/NILM/LSIL (i.e. a less severe lesion).Therefore, HSIL/CIN2+ was present in both the pap and bx in true positives (TP), and absent in both modalities in true negatives (TN). In false positives (FP), the pap showed HSIL while the bx showed less than a CIN2+. In false negatives (FN), paps displaying less than a HSIL were associated with biopsies displaying CIN2+. Combinations associated with ASC-US or ASC-H interpretations were excluded. All cytologic preparations were liquid-based. Results: A diagnostic discordance was present in 17 (4.8%) of 356 such pap test/bx combinations. The discordance was attributed, by virtue of having the less severe interpretation, to the pap test in all 17 cases. Using the cervical bx diagnoses as the gold standard, the sensitivity, specificity, positive predictive value and negative predictive value of the pap test in identifying a CIN2+ lesion was 50%, 100%, 100% and 95% respectively. There were 17, 322, 0, and 17 TP, TN, FP and FN respectively. Conclusions: In 4.8% (17/356) of cases, a bx-proven CIN2+ was not captured by the concurrently obtained pap test. This figure essentially represents the contemporary false-negative rate of the pap test in liquid-based cytologic preparations, and should be a consideration in screening programs. Background: The Susan G Komen for the Cure white paper (Breast J 13(5), 2007 443-47) identifies key issues that affect quality practice in breast pathology, including diagnostic accuracy, reimbursement, tissue banking, pathologist training, clinical team integration, and maintenance of the highest standards of practice. The purpose of this study is to describe how the above issues are addressed in an integrated quality assurance/ patient safety program in a pathology department of a womens hospital. Design: Preanalytic handling of biopsies include 10% formalin fixation time of 8-48 hours and 5 levels on each block. Analytic items include mandatory review of internal and referred material and halting scheduled surgery if there are diagnostic discrepancies. Daily review of difficult cases is documented for patient safety CME. Uniform problem-oriented panels for IHC studies are utilized. There is real-time review of FNAs accompanied by biopsies and secondary reviews of positive and negative biopsies. A postanalytic radiology-pathology correlation report is issued by radiology. Predictive/prognostic marker results are monitored to detect drift. Preanalytic resection specimen handling includes review of the core biopsy report to direct specimen handling. All tissue is submitted for a diagnoses of ADEH/DCIS in the absence of a gross lesion. Tissue banking is routine for all tissues. Postanalytic review includes tumor boards, OR consults and 5% random review. Pathologists and assistants are held to a quality program for recredentialling. Results: Discrepancies in breast biopsy diagnoses from outside institutions are 7%, with 50% of discrepancies potentially impacting patient management. Internal peer review measures indicate a very low incidence of significant discrepancies compared to the published literature. Conclusions: (1) Preanalytic measures assure optimal specimen handling and predictive/prognostic factor outcomes and uniform practice. (2) The quality analytic measures provide for an active collegial environment and exposure for trainees that fosters patient safety, maximizes diagnostic accuracy and reproducibility and minimizes risk. (3) Postanalytic analysis assures integration of radiology (rad-path correlation), surgery and oncology (tumor boards), and teaching function, by being a part of the entire process. (4) These measures, along with the complex specimen reporting requirements, have never been addressed from the reimbursement perspective, and there is a critical need for this to be done. Background: Critical values (CVs) are used in the area of clinical pathology to ensure patient safety; however, such practice has not been well-established in anatomic pathology. Recently, guidelines proposed by the Association of the Directors of Anatomic and Surgical Pathology (ADASP) were adopted and modified by our department. To evaluate our performance within these new guidelines, we monitored CVs in surgical pathology to improve patient safety. Design: In 2005, we established policies regarding timely communication and documentation of urgent surgical pathology findings, which has led to guidelines requiring immediate notification of primary clinicians. In 2006, we performed a 6-month, retrospective study for documentation and notification of CVs. To assess our progress, we studied a similar time frame this year and compared the results to determine the validity of our CVs and our compliance using newly revised/customized guidelines. Results: Of the 28,298 surgical pathology cases examined, excluding gynecologic pathology, neuropathology and cytology, 1,048 cases (3.7%) prompted urgent physician notification (3.2% in 2006) . In over half of the cases (694 cases, or 66.2%), the physician was contacted by telephone within 24 hours of receiving the specimen and the notification was documented in the report. The top three reasons that required physician notification were consistent with the previous year: kidney biopsies (321, 30.6%), malignancies (174, 15.3%) and transplant biopsies (245, 21.6%). 391 of the 1,048 cases (37.3%) fell within the ADASP proposed CV categories. Other cases which also prompted urgent contact include graft-versus-host disease (23), acute tubulointerstitial nephritis (102), and acute ischemic colitis (6). Our new policy requires CVs to be documented and "flagged" using our electronic system. 840 cases (80.2%) were both flagged and documented, while 191 cases (18.2%) were either documented (141) or flagged (50). 17 cases (1.6%) were not properly documented. (2006) . The study included a systematic analysis of all kidney biopsy reports to document the critical values and to monitor adherence to our established policy. Results: Of the total 733 kidney biopsies, the clinicians were communicated in 321 cases (4%) of the total kidney biopsies this year as compared to 218 cases (2%) last year. There were an increased in number of cases in many of the categories of critical value list, including crescentic glomerulonephritis, allograft biopsies and active interstitial nephritis (Table) . All cases were communicated within 24 hours based on the findings of the light and immunofluorescence microscopy. The average time spent by the pathologist in communication and documentation was estimated approximately over 8 minutes per case or 43 extra work hours over the 6 month period. Per our guidelines, all the cases were documented and "flagged" in our electronic system. Conclusions: Critical diagnoses in renal pathology requiring immediate physician notification represent a significant fraction (30.6%) of the total number of surgical pathology cases communicated in our department. This study demonstrates an increased awareness among the renal pathologists to relay critical values in an emergent fashion. Many medical kidney diagnoses require time-sensitive management; thus, our compliance to the guidelines facilitates the clinicians to expedite the treatment protocols, minimize further kidney damage, and ultimately improve patient care and safety.
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Mandatory Second Opinion in Cytopathology Referral Material N Lueck, CS Jensen, MB Cohen, JA Weydert. University of Iowa Carver College of Medicine, Iowa City, IA. Background: Mandatory review of outside pathologic material is intended to detect interpretive errors that may have a clinically significant impact on patient care. Prior to definitive treatment of referred patients, our institution requires a review of pertinent pathologic material previously obtained at outside institutions. The aims of this study were to determine if this local standard of practice has a measurable impact on patient care. Design: The pathologic diagnoses of 499 second opinion cytology cases seen at the University of Iowa Hospitals and Clinics were studied. Each second opinion was classified as 'no diagnostic disagreement', 'minor disagreement', or 'major disagreement' with respect to the originating institution's interpretation. A major diagnostic disagreement was defined either as: 1) a two step difference in opinion on a scale of "benign, atypical, suspicious and malignant" or 2), a diagnostic disagreement with a potential for a change in treatment or prognosis. The clinical impact of major disagreement cases was determined by pathologic and clinical follow-up via chart review. Results: Second opinion cytology resulted in 37 cases (7.4% of total cases) with major diagnostic disagreements and 55 cases (11.0%) with minor diagnostic disagreements. Clinical and pathologic follow-up was available in 30 of the major disagreement cases, and the second opinion diagnosis was better supported in 22 of these cases compared to the outside diagnosis. The second opinion in 6 major disagreement cases prompted changes in clinical management. The case-types that prompted a change in clinical management included: thyroid fine needle aspirations (3 cases), cervical-vaginal cytology (2 cases), and parotid fine needle aspiration (1 case). Conclusions: Major disagreements in second opinion cytology are common, likely reflective of the challenges inherent in the interpretation of cytologic specimens. Although mandatory second opinion of outside cytologic material prompted changes in clinical management in only a small fraction of cases (1.2%), this rate is similar to those previously published for surgical pathology second opinion. These findings support the notion that mandatory second opinion policy is an important part of patient care.
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High Risk for Carry-Over Artifacts in Routine Hematoxylin and Eosin Stainers L McDonald, P Sommer, AE Bennett, JL Hunt. Cleveland Clinic, Cleveland, OH. Background: Carry-over artifacts (floaters) can be introduced at every step in tissue processing. The Hematoxylin & Eosin (H&E) staining process has been implicated as a source for contaminants, but little experimental evidence exists. This study sought to experimentally address the question of whether a routine linear H&E stainer (so-called "dip and dunk") is a source for significant carry-over artifact. Design: Two staining machines were used to assess carry-over artifacts in the H&E staining process: A linear stainer (Leica Systems, Bannockburn, IL) and an automated discrete slide H&E stainer (Symphony, Ventana Medical Systems, Inc., Tucson, AZ). We extracted 20 ml of fluid from each staining bath on the linear stainer at the end of the day, three separate days. Cytospins were prepared and the slides were stained using the automated Symphony stainer and examined for tissue contaminants. In a second experiment, 3 blocks containing ten fragments of different types of tissue were created. 40 slides were cut from each block and alternating levels were stained on the Symphony discrete slide stainer and the linear stainer. The 120 slides were examined for carry-over artifact.
Results:
The staining solutions in the linear stainer were contaminated with tissue fragments. The fragments vary in size from 5-10 cells up to 50 or more cells. Many of the contaminating fragments were morphologically malignant. The contaminating fragments were concentrated in the first xylenes and first alcohols, but were seen occasionally all the way through the stain set up. In the second experiment, tissue from the sections could be seen displaced, presumably from discohesion or lifting of the sections. 45% of the slides stained on the linear stainer had these displaced tissue fragments and 22% of the slides stained on the Symphony stainer had displaced tissue fragments (p=0.007). Two slides from the linear stainer (3%) had foreign tissue fragment contaminants that were not from the tissue in the blocks (true tissue floaters). None of the slides from the discrete slide stainer had true tissue floaters.
Conclusions:
The linear H&E stainer is a source for potential carry-over artifacts and the contaminating tissue fragments in the stain solutions can be malignant. Because the early solutions are most frequently contaminated, efforts to change or clean solutions should concentrate on the initial xylenes and alcohol baths. The discrete slide stainer, with single use reagents, does not have the same risk of foreign contaminants.
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Using a Transcription's elimination modestly increased detected defects, standarization doubled them, but total defects fell 20 % with HFPS introduction and 40% more with its full integration into practice. Report defects rose to 2/3 of amendments with standardization, then to 3/4 of amendments with HFPS's integration. MIS-INTERP fell slightly with HFPS integration. MIS-ID rose with systematic amendment handling, and then fell with HFPS introduction and fell strikingly with HFPS's integration into practice operations. Sample defects remained few throughout. Conclusions: Removing transcription increased report defects and introducing systematic classification increased detection of defects in all categories. Introduction of the HFPS Lean intiative began to reduce defects in all categories and its full integration into practice reduced them further in MIS-INTERP and Report Defect categories. The amendment taxonomy identifies pathology defects and specifies outcomes of improvements aimed to reduce them. Background: Breast biopsies are performed for analysis of mammographic calcifications which may be associated with cancer. Occasionally, the confirmation of calcifications in initial slides isn't possible. This necessitates multiple recuts and may ultimately lead to conventional x-ray (XR) to assist in the identification. In our environment, the current XR process for calcifications is tedious and time-consuming as specimen imaging is accommodated in a busy radiology service. This increased turn around time (TAT) delayed the final reporting up to 7 days. Our response was to use Lean process redesign in the Henry Ford Production System to implement an intradepartmental digital X-Ray (DXR) imaging system to identify these targeted calcifications. This improvement dramatically decreased the TAT by allowing for earlier calcification identification in the gross pathology process which, in turn, allowed the pathologist to report a more timely final diagnosis. Design: Data were collected from a search of breast biopsies categorized into masses versus calcifications from March 2-April 5, 2006. Calcifications were further divided into those that required additional recuts for calcification identification and those that needed XR localization. The TAT and number of recuts for these cases were calculated from accession to signout in the CoPath information system. After implementation of the DXR, all cases for calcifications were imaged prior to histologic submission. Data were collected for TAT and recut data were compared subsequently from February 28-March 31, 2007. Results: In 2006, from 164 biopsy cases, there were 118(72%) masses and 46(28%) calcifications. Of the calcifications category, 31% required additional recuts (12 slidesmedian) and 40% of those cases required XR localization. The median TAT was 5 days. In 2007, of 193 biopsy cases, there were 145(75%) masses and 48(25%) calcifications. Of the calcification cases, 10% needed additional recuts (3 slides-median) and 100% of those cases were DXR prior to histologic submission. The median TAT was 2 days. Conclusions: Lean process redesign utilizing DXR up-front in the gross examination process of breast biopsies, has significantly improved TAT by 60% and number of recuts has reduced by 75% for breast biopsies for calcifications. This improvement in TAT and decrease in laboratory waste associated with unneeded recuts, has allowed our pathologists to report the final diagnosis in a timelier manner. Background: SLNB has emerged as an alternative to axillary lymph node dissection (ALND) in the staging of clinically node-negative breast cancer patients since it has less morbidity without compromising survival. We summarize our 8-year institutional experience and address a wide range of quality assurance questions around this practice. Design: Surgical pathology database was searched in the period 1999 to 2007 for all cases with IOC on SLNB in breast cancer patients. The complete operative procedure including additional surgery on the ipsilateral axilla was recorded. Number of sentinel nodes processed at the time of IOC, frozen and permanent section diagnoses, number of additional non-sentinel nodes and their status, tumor type, and whether the IOC diagnosis was rendered by a breast pathologist were analyzed. Chi square and Fisher's exact tests were used to determine differences between the groups. Results: 707 IOCs performed by frozen sections were identified. The median age was 58 years old (Range: 23-87). The mean number of sentinel nodes harvested was 2.4 per case. IOC was positive for metastatic carcinoma in 117/707 cases (16.5%) and the final pathology was positive in 158/707 cases (22.3%) with an overall false negative rate of 25.5% and accuracy of 94%. There were no false positive cases. The rate of false negative was not significantly associated with the histologic type (p = 0.76). When a breast pathologist rendered the IOC (n = 211), the false negative rate was 15.3%, sensitivity 84.5% and accuracy 97%. When a non-breast pathologist rendered the diagnosis (n = 496), the false negative rate increased to 29.4% (p = 0.08), sensitivity decreased to 70.6% and accuracy to 9%. The likelihood of missing a micrometastatic focus (≤2 mm) was not significant when the two groups were compared, but it was significantly higher for macrometastasis (> 2 mm) when non-breast pathologists rendered the diagnosis (p = 0.009). In 113/117 cases with positive IOC the surgeon proceeded with ALND and additional metastases in non-sentinel nodes were identified in 59 cases (52.2%). Conclusions: Regardless of the tumor histologic type, IOC for SLNB is a safe practice that can reliably save clinically node-negative patients a second surgery for lymph node dissection. In slightly more than half of the intraoperatively positive cases, other axillary lymph nodes will have metastases. It is less likely to miss a macrometastasis when breast pathologists render the IOC consultation. Background: Error and error reduction are a main focus of attention in quality assurance and quality improvement (QAI) programs in surgical pathology. Despite its importance, there have been few studies that utilize amended reports as quality improvement instruments. Amended reports provide crucial data, as they are the result of identified discrepancies by pathologists, clinicians, or any consultant reviewing this clinicopathologic correlation. Design: Our study evaluates the consequences of errors and develops methods for reducing them. We assessed the 455 amended reports (out of 107,642 surgical pathology cases or 0.42%) in a 2-year period using a computer program that identifies amended reports for future review. Analysis was based on a comparison between each original report and the corresponding amended report. Each of these reports was classified into 1 of 5 error types derived to facilitate prompt assessment of the causes for amendment. Errors related to diagnosis (types I and II) were sub-classified according to patient management effects. Gross description/clinical history errors (type III), typographical mistakes (type IV), misidentification errors (type V) and the quality of documented changes and report format were also studied. Results: Proposed classification categories and improvement actions are listed in the table, according to phase of report-processing (pre-analytical, analytical and postanalytical). Conclusions: Structured, continuous review of revised surgical pathology reports is a necessity. We propose a system of classification for amended report error type (five types) as a means for improving departmental quality and communication with clinicians. Depending upon error type, direct action may be taken to prevent recurrence. In addition to documentation of exact changes made within amended reports, notation of communicated report revisions to the clinician, within the revised document, is essential. A clear explanation of changes and consistent documentation of clinician notification standardizes error reporting and improves clinician-consultant communication, ultimately reflecting in quality of patient care.
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To Count or Not To Count: That Is the Question V Parkash, M Martel, D Jain, C Bifulco. Yale University, New Haven, CT. Background: Lymph node (LN) status, the single most important prognostic indicator of survival in a patient with cancer, is traditionally based on the number and location of tumor positive LNs. However, recent studies have shown that the total lymph node count is also of prognostic significance, and have stressed the importance of retrieving a minimal number of lymph nodes in order for the patient to be considered optimally staged. Despite these findings, the actual process of counting lymph nodes is currently not standardized. Design: The study was undertaken to determine the degree and significance of variations in the process of lymph node dissection and counting. A set of 15 H&E slides was circulated on two separate occasions with an intervening period of 2-30 days amongst 10 pathologists, 7 of whom practiced in a community hospital setting. Inter-and intra-observer differences amongst the pathologists were analyzed. This was followed by a targeted review session in which 4 areas were marked and re-circulated with a questionnaire to better understand the used individual criteria. Gross dissection was evaluated by reviewing the lymph node dissecting practices at two independent institutions participating in the study. Results: The total lymph node counts rendered on the submitted slide set ranged from 62-101, with no two pathologists giving the same total count. Slides with more than ten fragments and slides with the gross description of "single node palpated" had the greatest counting variability. Intra-observer disagreement was frequent, occurring 32% of times. The targeted review showed that different pathologists had different criteria about what constituted a lymph node. Size, the presence/absence of a capsule and subcapsular sinus, and the proximity two nodal structures were issues that the pathologists used to determine whether or not to count a lymphoid aggregate as a LN. The gross dissection of lymph nodes appeared to be relatively standardized at both institutions, with both using a combination of fat clearing, visualization techniques and palpation for the detection of lymph nodes. Conclusions: This study documents significant inter and intra-observer variation in LN counting amongst pathologists. We recommend that no more than five fragments of tissue be submitted in a single cassette and that all lymphoid tissue be counted as LN. Unless the actual process of LN counting is standardized, the minimal node count is likely to vary significantly between studies and a true minimal node count for staging cannot be reliably set. Design: The focus of this project was to examine the utility, quality and completeness of synoptic reports of the lung, colon, and endometrium. As of 2003, our institute has used a digital synoptic reporting system as part of existing laboratory information system (LIS), CoPathPlus. One hundred and Fifty cases were randomly selected from the LIS representing cases from lung and endometrium resections.A total of 100 reports were evaluated for the required CAP checklist elements in the free text and synoptic sections of the reports. Results: For the lung resection specimens, data indicated that majority of the 12 required CAP checklist elements were present in both the free text and the synoptic sections \ with the exception of 2 elements: surgical margin involvement (deficiency in 1 report) and surgical margin site (deficient in 11 reports). For endometrial carcinomas, deficiency is noted for 4 of 14 required CAP checklist elements including tumor type (2% deficient reports), nuclear grade (12% deficient reports), and tumor size (2% deficient report), and depth of invasion (4% deficient reports). Conclusions: Since the implementation of CAP checklists, there is paucity of information regarding the use of the checklists and their impact on reporting pathology data to the health care team, including the cancer registry, quality improvement departments, marketing, public health agencies and research databases. Our study illustrates that inspite of implementation of CAP checklists in our pathology reports, there are considerable deficiencies in the reports and 1 or more the required CAP checklist elements are missing from the pathology reports.
The Significance of Intraoperative Gross Examination of Margins on Patient's Management: A Breast Model A Plotkin, J Zubovits, C Holloway, S Nofech-Mozes. Sunnybrook Health Sciences
Centre, University of Toronto, Canada. Background: Local control is compromised in patients with positive or close margins after breast conserving surgery (BCS). Assessment of adequacy of margins on lumpectomy specimens with palpable lesions is a common indication for intraoperative consultation (IOC) in our practice. Inadequate resection margins that are identified intraoperatively can be immediately revised, potentially saving the patient a separate surgical procedure. We aimed to determine the accuracy of intraoperative margin assessment by gross inspection and estimate the rate of spared re-excisions in patients with invasive breast cancer undergoing BCS for which IOC was requested. Design: We identified 150 consecutive cases of BCS for invasive breast carcinoma in which the adequacy of margins was grossly assessed intraoperatively between [2005] [2006] [2007] . The size and status of the closest margin rendered at the time of IOC were compared with those of the final pathology of the initial specimen. Revision of margins in the same surgery and any re-excision at a later date were recorded. For the purpose of this analysis we defined potentially saved re-excisions as cases with positive or "close" margins that are 2 mm or less at the time of IOC. Results: IOC identified 30 cases with close/positive margins. The false negative rate was 45%, false positive rate 9%, sensitivity of gross assessment 54%, specificity 91%, and the accuracy was 82%. The initial margins were revised intraoperatively in 28/150 cases: in 17 cases due to the grossly assessed close/positive margins and in 11 cases at the surgeon's discretion. Ultimately, definite negative margins after intraoperative revision were achieved in 123/150 cases. In 14 cases re-excision was performed as a second surgical procedure. Based on gross assessment, there were 20 cases in which gross assessment identified correctly close/positive margin, in which a second re-excision operation could have been spared; 11/20 (55%) were revised in the same surgery all with definitive negative margins. Margins were not revised (9/20) whenever the involved margin was anterior or posterior. Conclusions: IOC using gross assessment of margins has low sensitivity. A second re-excision was avoided in 7% (11/150) of our patients sparing the cost and morbidity of additional surgery.
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The (Table  1) . Eleven event types were identified based upon perceived cause or association; the frequency of each was calculated ( Table 2 ). The potential severity and frequency of reported events were used to develop QIP focusing on specimen collection and handling, delayed reporting of results, transportation problems, failure to follow protocol, and enhancement of informational services. The effectiveness of using a standardized double case viewing protocol for prostate biopsy error detection across multiple institutions has not been established. Design: Four institutions (Loyola University, University of Iowa, University of Pittsburgh, Wake Forest University) implemented a standardized case-control study, in which specimens from the case period were blindly reviewed (pre-signout) by a second in-house pathologist. The cases from the control period were not double viewed. A total of 712 cases and 2459 case parts were double viewed. One institution previously reported their data, although this study focused on comparative findings and overall cancer proportion. We measured the malignancy and high grade prostatic intraepithelial neoplasia (HGPIN) rate by part and case, the number of total diagnostic disagreements, disagreements leading to major changes in clinical management (e.g., change from routine follow-up to rebiopsy or cancer treatment), and diagnostic disagreements from benign to malignant (or vice versa).
Results:
The mean institutional proportional difference between first and second reviewer diagnosis per case and part was 14.0% (range: 9.8%-16.5%) and 6.6% (range: 3.8%-11.8%), respectively. The mean institutional proportional diagnostic difference that had a major impact on clinical management per case and part was 10.6% (range: 5.8%-14.7%) and 5.1% (range: 3.4%-9.8%), respectively. The mean institutional proportional difference of a change from a benign to a malignant diagnosis (or vice versa) per case and part was 0.8% (range: 0%-2.9%) and 0.3% (range: 0%-1.0%), respectively. The detection of malignancy increased from the control to the case period at only one institution, although case malignancy (34.0%-49.1%) and HGPIN (2.1%-13.5%) rates were highly variable. Conclusions: Double case viewing had a variable institutional impact on error detection, most likely reflecting differences in pre-existing diagnostic standardization. Double case viewing had a high impact on changing clinical case management and rarely resulted in a change of diagnosis from benign to malignant (or vice versa). A larger study is needed to determine if double viewing affects overall malignancy rates; our data indicate that in some cases, the diagnosis is upgraded and in other cases it is downgraded, balancing out the overall malignancy rate.
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Effectiveness of Random and Focused Review in Detecting Anatomic Pathology Error SS Raab, AV Parwani, LK Mahood, DM Grzybicki. University of Pittsburgh, Pittsburgh, PA. Background: Different error detection methods yield different error proportions and have variable benefits for anatomic pathology divisions with limited quality assurance resources. We compared error detection proportions of a random review process and a focused review process. Design: We performed a non-concurrent cohort study at a large institution that practices subspecialty surgical pathology sign-out to compare the effectiveness of error detection using a targeted 5% pseudo-random review process and a focused review process. In the focused process, pathologists selected specific areas to review (e.g., core biopsy specimens from a particular organ type or an area of perceived high diagnostic interobserver variability). The institution was deidentified to encourage error reporting. From 2001 to 2006, pathologists reviewed 7,444 cases (3.5% of all surgical pathology cases) using a targeted 5% pseudo-random review process, and in 2006, pathologists reviewed 380 cases (0.70% of all cases) using a focused review process. Previously, individual errors detected by both processes have been presented, although this study was focused on the effectiveness of the method of case review. Reviewers subjectively classified errors as having potentially minor or major impact on patient care. We performed medical record reviews to determine the effect of major impact errors and graded impact severity using the categories of harm (subclassified by degree), no harm, and near miss. Results: The number of errors detected by the targeted 5% pseudo-random and focused review processes was 195 (2.6% of reviewed cases) and 50 (13.2%), respectively (P < 0.001). The number of major errors for the targeted 5% pseudo-random and focused review processes was 27 (0.36%) and 12 (3.2%), respectively (P < 0.001). Harm was seen in 17 (43%) of all major errors and moderate harm was associated with 2 (5.1%) major errors (0.026% of all reviewed cases). Conclusions: We conclude that compared to a targeted 5% pseudo-random review process, focused review detects a higher proportion of errors and may be more effectively used for design of error reduction initiatives such as diagnostic standardization procedures. The lack of diagnostic standardization rarely causes catastrophic events, but may be associated with low grade harm, such as repeat testing or diagnostic delays.
Interobserver Variability in the Diagnosis of Extranodal Extension of Malignancy
S Raphael, C Rowsell, C Macmillan, C Streutker, I Weinreb. University of Toronto, Toronto, ON, Canada. Background: The diagnosis of extranodal extension (ENE) of malignancy has become important in providing information of prognostic and therapeutic value for many oncology patients. This includes patients with malignancies commonly seen in the practice of surgical pathology, including patients with invasive duct carcinoma of breast, non-small cell carcinoma of lung, renal cell carcinoma, stage 3 colonic adenocarcinomas and squamous carcinomas of the head and neck. The usual definition of extranodal extension is tumor spreading beyond the lymph node capsule. Despite the frequency of this task for surgical pathologists we could find no study of the reliability of this diagnosis. Design: We presented 18 digitized images of lymph nodes containing metastatic tumor to 26 academic pathologists at 4 institutions, all affiliated with the University of Toronto. The images were drawn from cases of squamous carcinoma of the head and neck (5 cases) and colonic adenocarcinomas (4 cases). Pathologists were instructed to specify whether ENE was present or absent using the criteria they use in daily practice. Their answers were recorded on data sheets anonymously and no time restrictions were imposed. Results: The observed agreement for each image ranged from a high of 92% to a low of 54%. Although not offered as an option some pathologists diagnosed images as indeterminate for ENE. These diagnoses were offered 9 times in a total of 468 diagnoses. We counted these judgments as negative as no definite diagnosis of ENE had been made. The kappa statistic thus calculated was 0.44 (moderate agreement), p<0.0001. Conclusions: Our results showed moderate reliability between pathologists in diagnosing ENE. As we gave no instructions as to the definition of ENE, our results should closely approximate the daily practice of these academic pathologists. The major criticism of our study is that we used images rather than slides. We did this deliberately in order to present exactly the same image to our subjects. Our results are in the range of other studies of reliability in histological diagnosis, although most of these studies compare the original diagnosis to review diagnoses. In addition these studies often concern what are usually thought of as more difficult diagnoses (example Hodgkin's disease, cervical neoplasia). We suggest that a more precise and easily applied definition of ENE is necessary to disseminate among pathologists, in order to issue this diagnosis with more reliability. Background: Previous studies have reported an alarmingly low concordance between local laboratories and central laboratories in BC clinical trials for the determination of ER/PR and HER2 status. The objective of the XENA® trial was to show the rates of pathological complete (pCR) and near (npCR) and to confirm that the C+D (+/-trastuzumab) regimen known to be effective in the treatment of metastatic disease would also be efficacious when used in the neoadjuvant setting. Design: The XENA trial enrolled patients with newly diagnosed invasive HER2-/+ BC, T2N0-1M0 and T3N0-1M0, to determine the rate of (pCR) and npCR (T1a) in the affected breast after 4 cycles of neoadjuvant treatment with C+D (+T for HER2+ cases). 0 local laboratories determined the estrogen receptor (ER) and progesterone receptor (PR) by IHC and the HER2 status by either IHC or FISH on FFPE needle core biopsies. The central laboratory re-determined the ER/PR by IHC and HER2 by FISH (Inform®, Ventana Medical Systems, Tucson, AZ) on unstained slides of the core biopsies submitted by the local labs. Central lab HER2 FISH signals > 4.0 was considered as HER2+. Results: Of the 164 patients enrolled in the XENA trial, 155 (94%) were evaluable for all 3 biomarkers. For ER, 7 (5%) were discordant with 5/7 (71%) featuring local ERand central ER+. For PR, 20 (13%) were discordant. If weak PR positivity by central testing was considered negative, PR discordance was 16 (10%). For HER2, 1 (1%) were discordant with local reporting HER2-and central HER2+.
Conclusions:
In contrast with previous breast cancer clinical trial studies, the discordance between local and central labs for determining ER, PR and HER in patients enrolled in the XENA trial was extremely low. Of the 3 measured biomarkers, discordance in PR testing was highest (13%), intermediate for ER (5%) and lowest for HER2 (1%). Approaches to reduce discordance by the central lab in the XENA trial included 1) confirming that both labs tested the same tumor block, used similar techniques and cut-offs for ER and PR IHC, agreed upon thresholds for HER2+ by both IHC and FISH and that central lab used HER2+ gene copy only, not HER2/CEP17 ratio to judge concordance with local IHC.
1636
Low Lymph Node Count after Neoadjuvant Chemotherapy for Breast Cancer Should Not Be Assumed To Represent Complete Axillary Dissection S Sahoo, AB Chagpar. University of Louisville, Louisville, KY. Background: In patients with locally advanced breast cancer, neoadjuvant chemotherapy (NACT) has become the preferred initial treatment modality, followed by definite surgical therapy directed to the breast and the axilla. Although it is well documented that NACT reduces the number of tumor-involved lymph nodes, it s not clear how NACT affects the overall lymph node count in an axillary lymph node dissection (ALND). Design: Patients who received NACT followed by ALND were compared with patients who received surgery first. All patients received a level I and II axillary lymph node dissection at single institution by one breast surgeon. The number of lymph nodes between the two groups was compared using Mann-Whitney Rank Sum Test and Box plot. Results: A total of 36 neoadjuvant (age range 34 to 77 years, mean 52±10 years) and 38 surgery-first patients (age range 29 to 85 years, mean 53±11 years) were studied. The mean number of lymph node count in NACT group is 20±6, SEM 1.04 whereas the mean number of lymph node count in surgery first group is 20±9, SEM 1.4 (P=0.96).
Conclusions:
There is no significant difference in the number of axillary lymph node count retrieved at ALND in patients treated with NACT in comparison to surgery-first patients. Low lymph node count may be more common with NACT at certain institution as reported (Am J Surg 2006; 191:827-29) but may not be necessarily true at other institutions. Therefore, care should be followed to perform an adequate ALND as well as pathologic evaluation to obtain maximum yield of lymph node count to provide accurate information for staging.
1637
Standard Procurement, Processing and Reporting of Thyroid Fine Needle Aspiration (FNA) Improves Patient Care N Sidiropoulos, A Golding, F Quinlisk, JL Gonzalez, V Padmanabhan. Dartmouth Hitchcock Medical Center, Lebanon, NH. Background: Thyroid nodules (TN) occur commonly (Prevalance: 4-7%) and are assessed by FNA +/-ultrasound (U/S) guidance. A satisfactory sample that includes well-made smears is essential for interpretation and diagnosis. In our institution, we standardized collection, making and number of smears and reporting format for TN FNAs and evaluate the effect in the pre-and post-standardization (ST) groups. Design: Computer assisted search for all TN FNAs was performed between 9/24/04 and 8/29/07, including pre-ST data (TN FNAs performed by multiple MDs, +/-U/S guidance, smears made by different people) and post-ST data (U/S guided TN FNAs performed by a single endocrinologist yeilding 2 needle passes with 4 standard smears made by a single designated/trained nurse with additional pass material submitted in Cyto-rich red for cell block and H&E stain). Standard staining techniques were used (Papianicolou and diff-quick stain). Pathology reports were reviewed for satisfactory vs unsatisfactory procedure, satisfactory vs limited interpretation (LI), cytopathologic diagnosis and surgical follow-up (f/u). Results: 100 cases were identified in both groups with 120 pre-ST and 142 post-ST sites aspirated. The number of unsatisfactory specimens post-ST was reduced by 50% (Table 1) . Design: Sixty one prostate biopsies from patients with a diagnosis of GS7 adenocarcinoma, including 41 with pGP3 and 20 with pGP4 were selected. Slides from these tissues were stained using Feulgen. Areas of GP4 in all these cases were analyzed for 40 nuclear morphometric descriptors of the size, shape and chromatin using the CAS-200 system (Bacus Labs., Lombard, IL). Primary outcome analyzed was the ability of morphometric features to distinguish GP4 areas in the two subsets of GS7 tumors. Initial exploratory logistic regression (LR) analyses was performed to identify the best 1-through 4-parameter model. Discriminative ability of algorithms was tested using Receiver Operator Characteristic (ROC) curves. Results: There was no significant difference in the mean age, PSA and percentage of cancer between these two groups. LR yielded seven features that were significantly different (figure 1). Minimum nuclear diameter was selected as the most informative single-parameter model with a significant discriminative ability to distinguish GP4 areas in biopsies with GS 4+3 versus a GS of 3+4. [AUROC of 0.73 (95%CI: 0.63-0.88)].
Conclusions:
In this small cohort, we report presence of distinctive morphometric features in GP4 areas in the two sub-groups of GS7. These findings may aid in better risk stratification of the GS7 group by supplementing visual estimation of the percentages of pGP and pGP4 on the biopsy.
1639
The Value of Double Viewing Urine Cytology Specimens CM Vrbin, R Balassanian, DM Grzybicki, SS Raab. University of Pittsburgh, Pittsburgh, PA. Background: The practice of incorporating a double review process into anatomic pathology practice has demonstrated variable benefits, with some studies showing marginal benefit and others showing greater benefit. We measured the effectiveness of pre-sign out double review of urine cytology specimens diagnosed by the cytotechnologist or first pathologist as atypical. Design: Specimens in which the screening cytotechnologist or initial pathologist used a diagnosis of atypical were flagged for review by a second pathologist at a deidentified institution. In 2006, a total of 222 consecutive specimens were double viewed, 49% because of a screening cytotechnologist diagnosis, 23% because of an initial pathologist diagnosis and 28% because of an atypical diagnosis from both the screening cytotechnologist and initial pathologist. We performed clinical record review to measure the patient outcomes of downgraded and upgraded diagnoses. Results: The screening cytotechnologist diagnosed 170 urine specimens as atypical. The initial pathologist disagreed 64% of the time, downgrading the diagnosis 76% of the time and upgrading it 24% of the time. After the two pathologists reached consensus, the final sign-out diagnosis deferred from the screened diagnosis 68% of the time, with the diagnosis being downgraded to benign 72% of the time and upgraded to suspicious or malignant 28% of the time. The initial pathologist used the diagnosis of atypical in 114 cases. The review pathologist disagreed in 42% of the cases, downgrading the diagnosis 63% of the time and upgrading it 37% of the time. After the two pathologists reached consensus, the final sign-out diagnosis was changed from atypical 19% of the time; of these diagnoses 58% were downgraded to benign and 42% were upgraded to suspicious or malignant. Clinical outcome, based on medical record review, correlated with the changed diagnosis in 80% of cases. Conclusions: We conclude that double viewing initially diagnosed atypical urine cytology specimens resulted in a high degree of variability in diagnostic interpretation. Double viewing atypical urine specimens lowered the percentage of cases diagnosed as atypical in approximately 1 of every 5 cases. We found that double viewing improved diagnostic accuracy, resulted in improved patient triage that correlated with the clinical outcome, and resulted in greater diagnostic standardization. These data indicate that double viewing improved patient care for this specific indeterminate diagnosis.
1640
Comparison Background: Pre-operative diagnosis by fine needle aspiration biopsy (FNAB) is the standard of care in the management of thyroid nodules. Over the last decade there has been a change in the cytopreparatory techniques for evaluation of FNAB specimens. While earlier on it was mainly examination of conventional direct smears (smear) made by spreading the aspirated material on the glass slide, more recently for the past several years liquid based cytology for the thinprep process (Cytyc, Boxborough, MA) has become the preferred method of evaluating FNAB. The aim of our study was to compare the two methods in the diagnosis of thyroid FNAB specimens. Design: All thyroid cytology and surgical pathology (lobectomy and total thyroidectomy) specimens received in our department over a 10-year period (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) were retrieved from the archives. Thyroid surgical pathology specimens with the final pathological diagnosis served as the gold standard for comparing thyroid FNAB diagnosis. Patient's who had both the surgical pathology specimen and the FNAB formed the study group. Cytology reports were reviewed to make a note of the diagnosis and cytopreparatory method used for every case. Sensitivity and specificity for diagnosis of thyroid malignancy by FNAB was calculated and compared for both (thinprep & smear) cytological preparations. Results: In our department from 1997-2007 total of 693 patients' had both thyroid FNAB and surgical resection specimens accessioned, of these 290 were smear and 403 thinprep specimens. In the 5-year period from 1997-2002 out of a total of 08 thyroid FNAB specimens only 13 (4%) were thinprep, for the later 5-year period (2002) (2003) (2004) (2005) (2006) (2007) ) the number of thinprep specimens increased to 61 out of 85 (94%). Of the total 40 thinprep cases 20 (5%) were unsatisfactory, while this figure for smear type specimens was 36/290 (12%). The sensitivity for diagnosing thyroid malignancy with thinprep and smear was 87% and 84% and the specificity was 93% and 89% respectively. There were 12/194 (6%) false positive thyroid FNAB diagnosis by thinprep compared to 15/166 (13%) by smear. Conclusions: There has been a dramatic change in the cytopreparatory technique from conventional smear to thinprep cytology for the past 5 years. Thinprep processing is a better than smear technique for evaluation of thyroid FNAB specimens with better sensitivity, specificity and fewer non-diagnostic specimens.
1641
Digging Deeper: An Analysis of Cutting Deeper Levels on Skin Specimens AL Wilson, WG Watkin. Evanston Northwestern Healthcare, Evanston, IL; Northwestern University, Chicago, IL. Background: Pathologists obtain step sections (deeper levels) when initial sections are not considered fully diagnostic. While often necessary, serial sectioning leads to increased turnaround time, labor, and material costs, and sometimes tissue loss due to re-trimming of the paraffin block. In our laboratory, skin specimens are the most common tissue type on which deeper levels are requested (14.9 % overall). We analyzed multiple parameters which might contribute to the necessity of examining deeper levels in the hope of developing strategies to decrease the deeper level ordering rate. Design: Data analysis was performed on the first 200 skin specimens from 2005 which had deeper levels ordered and the first 200 which did not (controls). The following factors were analyzed: specimen type (shave, punch, excision), specimen size, whether the specimen was submitted whole or sectioned, the clinical impression, the final diagnosis, and the experience of the pathologist. We also compared the turnaround times between the two groups. Results: Smaller specimen size (p<0.0001), punch biopsies (p<0.0001), specimens submitted whole (p<0.0001), and cases with a clinical impression of cancer/dysplasia (p=0.0002) correlated with a higher rate of deeper levels. There were 102 punch biopsies; 77% had deeper levels. Of the 200 specimens submitted for deeper levels, 76% had been submitted whole. Of specimens which required deeper levels, 80% measured 0.5 cm or less; additionally, 60% of specimens which measured 0.5 cm or less required deeper levels. Pathologists with more years of experience ordered more deeper levels (p<0.0001), as did the board-certified dermatopathologist (p<0.0001). Deeper levels were ordered more frequently when the final diagnosis did not match the clinical impression (p<0.0001). A benign or malignant final diagnosis did not affect the deeper level ordering rate. The turnaround time was significantly longer in specimens with deeper levels compared with controls (average of 3.96 and 1.45 days, respectively, p<0.0001).
